Optimizing discharge planning: Clinical predictors of longer stay after recombinant tissue plasminogen activator for acute stroke

Stroke

Volumn 36, Issue 1, 2005, Pages 147-150

  Saposnik, Gustavo ^a,b   Webster, Fiona ^a   O'Callaghan, Chris ^a   Hachinski, Vladimir ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Complications; Hospitalization; Outcome; Prognosis; Stroke; Thrombolytic therapy; Tissue plasminogen activator

Indexed keywords

ALTEPLASE;

AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; DEMOGRAPHY; DISEASE COURSE; DRUG EFFECT; FEMALE; FIBRINOLYTIC THERAPY; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; RANKIN SCALE; STROKE; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; CEREBROVASCULAR ACCIDENT; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LENGTH OF STAY; MALE; PATIENT DISCHARGE; PROGNOSIS; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 11144220108     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000150492.12838.66     Document Type: Article

References (17)

1. Caro JJ, Huybrechts KF, Duchesne I. Management patterns and costs of acute ischemic stroke: an international study. For the Stroke Economic Analysis Group. Stroke. 2000;31:582-590.
2. Samsa GP, Bian J, Lipscomb J, Matchar DB. Epidemiology of recurrent cerebral infarction: a medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke. 1999;30:338-349.
3. Tu JV, Gong Y. Trends in treatment and outcomes for acute stroke patients in Ontario, 1992-1998. Arch Intern Med. 2003;163:293-297.
4. van Straten A, van der Meulen JH, van den Bos GA, Limburg M. Length of hospital stay and discharge delays in stroke patients. Stroke. 1997;28:137-140.
5. Chang KC, Tseng MC, Weng HH, Lin YH, Liou CW, Tan TY. Prediction of length of stay of first-ever ischemic stroke. Stroke. 2002;33:2670-2674.
6. Caro JJ, Huybrechts KF, Kelley HE. Predicting treatment costs after acute ischemic stroke on the basis of patient characteristics at presentation and early dysfunction. Stroke. 2001;32:100-106.
7. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). J Am Med Assoc. 1995;274:1017-1025.
8. Pagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Levine SR, Broderick JP, Kwiatkowski TG, Frankel M, Brott TG, Walker MD. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998;50:883-890.
9. Merino JG, Silver B, Wong E, Foell B, Demaerschalk B, Tamayo A, Poncha F, Hachinski V; Southwestern Ontario Stroke Program. Extending tissue plasminogen activator use to community and rural stroke patients. Stroke. 2002;33:141-146.
10. Saposnik G, Young B, Silver B, Di Legge S, Webster F, Beletsky V, Jain V, Nilanont Y, Hachinski V. Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy. J Am Med Assoc. 2004;292:1839-1844.
11. Williams LS, Rotich J, Qi R, Fineberg N, Espay A, Bruno A, Fineberg SE, Tierney WR. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology. 2002;59:67-71.
12. Wade DT, Langton Hewer R. Hospital admission for acute stroke: who, for how long, and to what effect? J Epidemiol Community Health. 1985;39:347-352.
13. Sinclair SE, Frighetto L, Loewen PS, Sunderji R, Teal P, Pagan SC, et al. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics. 2001;19:927-936.
14. Patel A, Knapp M, Ferez I, Evans A, Kalra L. Alternative strategies for stroke care: cost-effectiveness and cost-utility analyses from a prospective randomized controlled trial. Stroke. 2004;35:196-203.
15. Galski T, Bruno RL, Zorowitz R, Walker J. Predicting length of stay, functional outcome, and aftercare in the rehabilitation of stroke patients. The dominant role of higher-order cognition. Stroke. 1993;24:1794-1800.
16. Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. NINDS; The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Stroke. 2000;31:2912-2919.
17. Chapman KM, Woolfenden AR, Graeb D, Johnston DC, Beckman J, Schulzer M, Teal PA. Intravenous tissue plasminogen activator for acute ischemic stroke: a Canadian hospital's experience. Stroke. 2000;31:2920-2924.